Hair loss is often framed as a hormonal problem — too much DHT, not enough growth stimulation. This framing is accurate but incomplete. Scalp inflammation is an important, often overlooked contributor to hair loss that operates in parallel with hormonal mechanisms and can drive loss independently of DHT levels.
The Follicle and Its Immune Privilege
Hair follicles have a property called immune privilege, a state of reduced immune surveillance that protects the follicle from autoimmune attack. This privilege is maintained by a range of immunosuppressive factors produced by the follicle itself and by Treg cells in the follicle environment.
When this immune privilege is disrupted, the follicle becomes vulnerable to attack by immune cells. This is the mechanism behind alopecia areata, in which T cells target hair follicles and disrupt hair growth. It is also relevant to conditions such as lichen planopilaris and frontal fibrosing alopecia, in which chronic inflammation at the follicle leads to scarring and permanent loss.
Even in androgenetic alopecia — a non-autoimmune condition — subclinical inflammation around the follicle is common and appears to contribute to disease progression.
The hair follicle depends on immune privilege for normal cycling. When that privilege is disturbed by inflammation, follicle function is impaired, and hair loss accelerates.
Microinflammation in Androgenic Alopecia
A landmark 2000 paper by Mahe and colleagues examined scalp biopsies from men with androgenetic alopecia and found evidence of perifollicular microinflammation — inflammation surrounding the follicle — in over 40% of cases, even in early-stage disease. This was significantly higher than in control scalps without androgenetic alopecia.
The inflammatory infiltrate consisted primarily of lymphocytes and mast cells, and it was concentrated around the follicle bulge — the region of the follicle that houses the stem cells responsible for hair regeneration. Inflammation in this zone is particularly damaging because it impairs the stem cell population that drives hair regrowth.
In later stages of androgenetic alopecia, this microinflammation can contribute to follicular scarring: fibrosis around the follicle that some authors believe may contribute to miniaturization.
This may explain why some men do not fully recover even with aggressive DHT suppression.
Perifollicular microinflammation is present in over 40% of early androgenetic alopecia cases. It damages the follicle's stem cell reservoir and may accelerate the transition from reversible to permanent loss.
Seborrheic Dermatitis and Hair Loss
Seborrheic dermatitis is one of the most common scalp conditions, affecting about 1–3% of the general population and up to 34–83% of immunocompromised individuals. It presents as flaky, itchy, reddened scalp skin driven by an inflammatory response to Malassezia yeast.
The connection to hair loss is well established. A 2002 study found a significant positive correlation between seborrheic dermatitis severity and hair loss severity. The proposed mechanisms include:
- ● Direct follicular damage from the inflammatory process
- ● Physical disruption of the follicle opening by scaling and crust formation
- ● Potential amplification of androgenetic alopecia in susceptible individuals
Treating seborrheic dermatitis with ketoconazole or zinc pyrithione shampoos has been shown to reduce scalp inflammation and, in some studies, improve hair density.
Seborrheic dermatitis is both a contributor to hair loss and a treatable one. Controlling the inflammatory response with antifungal treatment removes one of the factors driving hair loss.
Alopecia Areata: Inflammation as the Primary Driver
Alopecia areata is an autoimmune condition in which T cells attack the hair follicle, disrupting the immune privilege that protects it. Loss is patchy and unpredictable and can affect any hair-bearing area of the body. Its presentation can range from a single small patch to complete scalp or body hair loss.
The condition is immune-mediated, not hormonal. DHT-targeting treatments have no effect on alopecia areata. Treatments that address the immune dysfunction — topical or intralesional corticosteroids, topical immunotherapy, and, more recently, JAK inhibitors — are the standard of care.
Baricitinib and ritlecitinib, both JAK inhibitors, have received FDA approval for severe alopecia areata in recent years, representing a significant advance in treatment for a condition that was previously very difficult to manage.
Alopecia areata is inflammation-driven, not DHT-driven. It requires anti-inflammatory or immunomodulatory treatment, not 5-alpha reductase inhibitors.
Lichen Planopilaris and Frontal Fibrosing Alopecia
Lichen planopilaris (LPP) and its variant frontal fibrosing alopecia (FFA) are inflammatory scarring alopecias. These are hair loss types where chronic lymphocytic inflammation around the follicle leads to fibrosis and permanent hair loss.
LPP presents with perifollicular redness, scaling, and pain or itch, typically affecting the vertex.
FFA presents with a band-like recession of the hairline, along with loss of eyebrows and eyelashes in many cases.
Both conditions require early diagnosis and treatment to preserve the follicles that have not yet been scarred. Once scarring occurs, regrowth is not possible. Treatment typically involves anti-inflammatory medications: topical or oral corticosteroids, hydroxychloroquine, or antibiotics with anti-inflammatory properties.
Scarring alopecias are irreversible once fibrosis is established. Early recognition and anti-inflammatory treatment are the only ways to preserve the remaining follicle population.
How to Address Scalp Inflammation
For patients with androgenetic alopecia complicated by scalp inflammation, several interventions target the inflammatory component:
- Ketoconazole shampoo (2%): Reduces Malassezia colonization and scalp inflammation. Has shown modest benefits in hair density independent of its antifungal action.
- Topical cetirizine (1%): Reduces PGD2 activity and scalp inflammation. Discussed in depth in Article 8.
- Zinc pyrithione: Reduces Malassezia and has mild anti-inflammatory properties.
- Pyrithione zinc in combination with minoxidil: Some evidence that reducing scalp inflammation enhances minoxidil response.
- Low-level laser therapy: Has shown anti-inflammatory effects alongside growth stimulation.
Targeting scalp inflammation is not a replacement for treating the hormonal driver of androgenetic alopecia. It removes a compounding factor that may be accelerating loss and reducing treatment response.
The Bottom Line
Scalp inflammation contributes to hair loss through multiple mechanisms: direct damage to follicles, impairment of the stem cell reservoir, elevation of growth-inhibiting prostaglandins, and, in advanced cases, scarring that renders the loss permanent. In androgenetic alopecia, subclinical microinflammation is present in a significant percentage of cases and may accelerate progression. In conditions like seborrheic dermatitis, alopecia areata, and scarring alopecias, inflammation is the primary driver of loss. Addressing inflammation — through ketoconazole, cetirizine, antifungal treatment, or condition-specific therapies — is an important component of comprehensive hair loss management.